A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes

Mine Harada, Tsunefumi Shibuya, Takanori Teshima, Masahiro Murakawa, Takashi Okamura, Yoshiyuki Niho, Hisashi Gondo, Shin Hayashi, Koichi Akashi, Kazuo Tamura, Shigeyoshi Makino, Hideyo Natori, Koichiro Egami, Shusuke Hisano, Eiji Morioka, Shuichi Taniguchi, Kazuo Yamazaki, Yujiro Yamano, Fusayuki Omori

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

We performed a randomized phase II trial comparing low-dose aclarubicin (LC-ACR) with very low-dose cytosine arabinoside (VLD-AC) in 39 consecutive untreated patients with myelodysplastic syndromes (MDS), including refractory anemia (RA), RA with excess of blasts (RAEB) and RAEB in transformation (RAEB-t). Nineteen patients received the VLD-AC therapy; 2 good responses (GR) and 2 partial responses (PR) were obtained in 11 patients with RAEB and RAEB-t, while 2 PR were obtained in 8 RA patients. Eighteen patients received the LD-ACR therapy; 2 GR and 4 PR were obtained in 11 RAEB/RAEB-t patients while 2 PR in 7 RA patients. There was no significant difference in the therapeutic effects and survival between these two groups of patients. These observations suggest that the LD-ACR therapy is effective in some patients with MDS and can be used as an alternative to the low-dose Ara-C therapy.

Original languageEnglish
Pages (from-to)629-632
Number of pages4
JournalLeukemia Research
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 1993
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this